The complement pathway has potential contributions to both white (WM) and grey matter (GM) pathology in Multiple Sclerosis (MS). A quantitative assessment of complement involvement is lacking. Here we describe the use of Tissue MicroArray (TMA) methodology in conjunction with immunohistochemistry to investigate the localization of complement pathway proteins in progressive MS cortical GM and subcortical WM. Antibodies targeting complement proteins C1q, C3b, regulatory proteins C1 inhibitor (C1INH, complement receptor 1 (CR1), clusterin, factor H (FH) and the C5a anaphylatoxin receptor (C5aR) were utilised alongside standard markers of tissue pathology. All stained slides were digitised for quantitative analysis. We found that numbers of cells immunolabelled for HLA-DR, GFAP, C5aR, C1q and C3b were increased in WM lesions (WML) and GM lesions (GML) compared to normal appearing WM (NAWM) and GM (NAGM), respectively. The complement regulators C1INH, CR1, FH and clusterin were more abundant in WM lesions, while the number of C1q1 neurons were increased and the number of C1INH1, clusterin1, FH1 and CR11 neurons decreased in GM lesions. The number of complement component positive cells (C1q, C3b) correlated with complement regulator expression in WM, but there was no statistical association between complement activation and regulator expression in the GM. We conclude that TMA methodology and quantitative analysis provides evidence of complement dysregulation in MS GML, including an association of the numerical density of C1q1 cells with tissue lesions. Our work confirms that complement activation and dysregulation occur in all cases of progressive MS and suggest that complement may provide potential biomarkers of the disease.
INTRODUCTION
Pathology in multiple sclerosis (MS) is typified by white matter lesions (WML), with characteristic inflammation, demyelination and axonal loss (neuro-degeneration) (12, 18, 19, 25) . Lesions are also found in sub-cortical and cortical gray matter (GML), the latter being a hallmark of the progressive phase (2, 4, 7, 14, 17, 22, 27, 29, 30) .
There is an urgent need to uncover the components of the CNS inflammatory response responsible for white and gray matter pathology in progressive MS in order to inform therapies that slow pathological and neurological decline. Among the implicated components, there is growing pathological evidence for a significant contribution of complement (C), to neuro-inflammation in MS (3, 5, 14, 16, 21, 23, 37) .
Activation of C is a major driver of inflammation and pivotal to innate and adaptive immune responses (24) . Glia and neurons synthesize the classical pathway activation protein C1q, which binds numerous potential ligands to initiate activation and generation of active products, including the lytic membrane attack complex (MAC) and the anaphylactic/chemotactic peptides C3a and C5a, chemoattractants for microglia expressing C5aR (8, 38) . To limit self-injury, neurons and glia express numerous C regulatory proteins (CReg) including C1INH (C1 activation blockade), CR1, FH (alternative pathway regulation) and clusterin (MAC assembly inhibition) (38) .
We have previously reported detailed quantitative immunohistochemical studies of complement proteins, activators and regulators, showing increased C in plaque, peri-plaque and NAWM of progressive MS compared with normal non-inflammatory control tissue (16) as well as in cortical gray matter lesions compared with non-inflamed control tissue (37) . Other studies in MS have focused on determining cellular localization of individual C proteins (1, 5, 21) . Here, to better understand the role of C activation and regulation in progressive MS we have used tissue microarray (TMA) methodology (36) , quantitative pathology and statistical analysis. This approach provides an unbiased, high throughput methodology for analyzing tissue for localization of key C proteins and regulators that can be correlated with measures of pathology in white and gray matter MS lesions.
MATERIAL AND METHODS

Post-mortem cohort
Archived formalin fixed paraffin embedded (FFPE) tissue blocks obtained at autopsy from clinically and neuropathologically validated progressive MS cases were provided by the Multiple Sclerosis Tissue Bank Imperial College, London, under South East Wales Research Ethics committee approval [10/WSE02/4]). Tissue blocks were sampled from neocortex (WM and GM) and subcortical (WM and GM) sites.
Fourteen blocks from 13 cases of progressive MS were used: mean age 51.1 years (38-79); clinical diagnosis: 9 secondary progressive MS (SPMS) (2 different FFPE blocks were used for case MS230): 4 primary progressive MS (PPMS). Clinical information, including age, sex, clinical onset and disease course are presented in Table 1 .
FFPE tissue blocks were obtained from cases of Alzheimer's disease (n 5 4; frontal and temporal lobe) and Herpes Simplex virus encephalitis (n 5 2; temporal lobe; supplied by Brains for Dementia Research, Institute of Psychiatry Kings College, London, UK and The Thomas Willis Brain Bank, Oxford University, Oxford, UK) as positive staining controls for this study. All blocks were stained with the same antibodies, in the same experimental run, as the TMA cores (Table 2 , Supporting Information Figures S1-S3).
FFPE tissue blocks were also obtained from control noninflammatory brain tissue cortex of three cases; CO38, CO40, CO41 (see Table 2 for clinical details and tissue preservation times), as described in the control cohort of Ingram and Loveless (16) . Tissue blocks were provided by the Multiple Sclerosis Tissue Bank Imperial College, London.
Lesion classification
From each FFPE block, 4 micron sections were cut and stained with hematoxylin & eosin (H&E) and Luxol fast blue (LFB). Immunohistochemistry for lesion classification was performed following deparaffinization and rehydration through a graded series of ethanol : H 2 O mixtures. Antigen retrieval was performed using 0.05% citraconic anhydride (pH 7.4; Sigma) and all immunohistochemistry (IHC) was performed using a DAKO autostainer, as previously described (16) .
Lesion classification was based on staining with the following antibody panel: anti-HLA-DR, anti-Iba (ionized calcium binding adaptor molecule 1, microglia marker), anti-MOG (myelin oligodendrocyte glycoprotein), anti-CD20 (B lymphocyte marker) and anti-CD3 (pan-T lymphocyte marker) (see Table 3 ).
Identification of demyelinated white matter and gray matter lesions for TMA construction
Conventional histological staining with H&E, LFB, anti-HLA and anti-MOG identified areas containing WML or GML. Applying criteria described by Lassmann (18, 19) , all WML selected were classified as slowly expanding-chronic active plaques (residual inflammation in center of demyelinated plaque with peripheral boundary of activated microglia/macrophages containing myelin degradation products). Cortical GML were classified as type I (involving cortical GM and subcortical WM), type II (intracortical) or type III (involving the subpial layers of the neocortex) cortical GML based on location, according to Peterson (26) . WML and GML immunolabeling for B and T cell lymphocytes was restricted to a perivascular and meningeal distribution in all sections (16). (36) . A Beecher MTA-1 manual tissue arrayer (Estigen OU, Tartu, Estonia), with a needle punch of diameter 0.6 mm, was inserted into the marked areas on the donor blocks corresponding to the site of the lesion. The donor tissue core was inserted into the recipient paraffin wax block according to the array coordinates defined in the predetermined template. Two TMA wax blocks were assembled; one containing 120 tissue cores, the other, 110 cores taken from the 14 individual FFPE donor blocks, as described. In total, 224 tissue cores were available for analysis (6 were not usable) with WM (n 5 51), WML (n 5 82; including WM lesion center and WM lesion edge), GM (n 5 56), GML (n 5 35; including GM lesion center and GM lesion edge) (see Figure 1 ).
Immunohistochemistry
From each TMA block, 4 micron thick sections were cut. The following antibodies were used to detect C activation proteins and CReg; mAb C3-30 (detects opsonins C3b and iC3b), anti-C1q, anti-C1INH, anti-CR1, anti-clusterin, anti-C5aR. A panel of three anti-FH antibodies and a mAb (MBC-125) recognizing FH-related proteins 1, 2 and 5 (FHR 1,2,5) were included to differentiate staining for FH and the FHRs. Sections from the TMAs, control inflammatory brain tissue and control non-inflammatory brain tissue, as detailed above, were processed and stained as described (see Table 3 for antibody details and staining conditions, and Supporting Information Figures S1-S3). Appropriate isotype-staining with anti-IgG1 antibody using control and negative control tissue were also included with each using methods described (16, 37) . Anti-fibrinogen antibody was used to stain paraffin wax sections of kidney, TMA and control non-inflamed cortex cases (see Supporting Information Figure S1 ).
In situ hybridization
In situ hybridization (ISH) was performed using a 5 0 fluorescein (FAM)-labeled 19mer antisense oligonucleotide containing nucleic acid (LNA) and 2 0 -O-methyl (2 0 -O-Me)-RNA moieties in a 1:2 ratio. Probes: antisense C1QA (NM_015991) FAM-TggTccTug AugTuuCcu; scrambled C1QA FAM-GuuGuuCggTcuCuaGucT; antisense C3 (NM_000064) FAM-TaaTccAccAauCauTucT; sense C3 FAM-AgaAauGauUggUggAuuA (capitals indicate LNA and lower case 2 0 -O-Me RNA; Eurogentec, Southampton, UK). Following de-waxing, rehydration and antigen retrieval, sections were prehybridized in hybridization mix (37) before probe hybridization for 30 min in the same solution. Sections were then washed in decreasing concentrations of saline-sodium citrate buffer, washed in PBS, incubated with a peroxidase conjugated goat anti-FAM (Vector Labs) and visualized with DAB. Sections were then blocked, incubated with mouse anti-Human HuC/HuD neuronal protein overnight (clone 16A11, ThermoFisher Scientific), followed by a horse anti-mouse biotin conjugated secondary, an avidin-biotin-AP tertiary and Vector Blue AP substrate (all Vector Labs), Sections were dehydrated, cleared in histoclear and coverslipped in VectaMount (Vector Labs).
Quantification of TMA immunolabeling
Individual immunolabeled TMA cores were digitally imaged (Zeiss Mirax slide scanner and Pannoramic Viewer 3DHistech software). Quantification was performed manually using Image J software ) for each C protein or cell phenotype marker was calculated and statistical analysis carried out using R v3 0.2 software (https://www.R-project.org/).
Statistical analysis
Comparisons in NAWM versus WML and NAGM versus GML of the total number of immunolabeled cells for each antibody-stained core was performed using Mann-Whitney U tests and significance taken if P < 0.05. For each tissue of interest, numbers of immunolabeled cells were counted for individual tissue cores; three separate cores were obtained from each lesion or normal tissue sample.
In order to examine the relationship between individual pairs of anti-C antibodies, the number of cells staining positively for each antibody was used as a continuous variable. Pearson correlation was used to examine the relationship between pairs of anti-C antibodies. All statistical analysis was performed using R v3 0.2 software (https://www.R-project.org/).
RESULTS
Anti-fibrinogen staining kidney and brain tissues
Kidney sections stained with anti-fibrinogen antibody (see Table 3 for details) demonstrated positive immunostaining. In brain, cortical anti-fibrinogen antibody staining was localized to blood vessel walls but was absent in nearby neurons and surrounding neuropil, indicating a lack of blood-brain barrier disruption (Supporting Information Figure S1 ); this interpretation was in accord with the findings of van Horssen et al (35) . Similar results were obtained using anti-IgG on control brain tissues showing no evidence for staining of neurons or glia in accord with published results (16) and supporting the lack of anti-fibrinogen staining interpretation as demonstrating an intact blood brain barrier.
Control non-inflamed brain tissue
Formalin fixed sections from three cases of non-inflamed cortex (C038, CO40, CO41, Table 2 ) were stained with the same anti-C antibodies as used for the TMA sections (Supporting Information Figure S1 ). In all cases there was minimal positive immunostaining of neurons and glia replicating our previous results for non-inflamed cortex (16) . There were significantly lower numbers of immunostained neurons and glia in control non-inflamed tissue as compared with NAWM and NAGM in MS tissue (16) . The non-inflamed tissues in this study were from the same cohort as the previous study.
Neurons and glia from cases of other neuroinflammatory diseases were often positively stained with anti-C antibodies; examples of typical staining patterns are shown in the supplemental data (Supporting Information Figures S2 and S3 ).
Astrocytic and microglia activation correlate with elevated numbers of C5aR-positive cells
We compared cores taken from NAGM, GML, NAWM and WML (Figures 1 and 2 ) areas in TMA preparations to better understand the role of complement activation in demyelinating lesions. Astrocytes (GFAP1) were found in higher numbers in WML (P < 0.0001) in comparison to NAWM (Figure 2A ). There was a significant increase of GFAP1 cells in GML, (P < 0.0001), compared with NAGM. GFAP1 astrocytes represented only approximately 10% of total glia in lesion tissue. There was no difference in the number of Iba-1 immunolabeled microglia in either WML or GML compared with NAWM or NAGM, respectively; however, HLA-DR1 activated microglia were increased in WML (P < 0.0001), as compared with NAWM, and in GML compared with NAGM (P < 0.0001). In all tissue types, microglia represented the most frequent immunolabeled cell type (Figure 2A) .
Anti-C5aR antibody positively immunostained microglia and a small number of cells with an astrocytic morphology; neurons were negative for C5aR as previously reported (22) . C5aR positive cells were increased in WML in comparison to matched NAWM (P < 0.003, Figure 2B ).
Immunolabeling for C component proteins and regulators in lesion versus non-lesion tissue
Total number of C1q immunolabeled cells was increased in WML and GML tissue compared with NAWM (P < 3 3 10
28
) and NAGM (P < 0.007), respectively ( Figure 3A ). Total number of C3b immunopositive cells per core was also increased in WML and GML tissue compared with NAWM (P < 0.0009) and NAGM (P < 0.03), respectively ( Figure 3B ).
We performed ISH for C1QA and C3 mRNA to test whether cortical neurons are a source of complement in the MS brain (Figure 3) . Transcripts of C1QA and C3 were detected in the soma of numerous cortical neurons that were immunostained for the pan-neuronal protein HuC/D. Sections incubated in the absence of probe (not shown), or with scrambled or sense probe, were negative ( Figure 3) . C1INH-positive glia were increased in WML compared with NAWM (P 5 2.7 3 10
25
; Figure 4A ). CR1-positive immunolabeled cells were increased in WML tissue compared with NAWM (P < 0.001) ( Figure 4B ). FH-immunolabeled glial cells were increased in WML in comparison to NAWM, detected using polyclonal (P < 0.005) and monoclonal antibodies against distinct FH regions (Ox-24 vs. FH N-terminus; MBI-15 vs. SCRs 11-15; both P < 0.01) ( Figure 4C,E,F) . MBI-15 stains only FH (not FHL or FHRs); staining with polyclonal anti-FH and MBI-15 were highly correlated in all TMA cores (R 2 5 0.69) and for neuronal staining (R 2 5 0.83; data not shown). Immunolabeling with MBC-125, specific for FH-related (FHR) proteins 1, 2 and 5 (present as heterooligomers in vivo), demonstrated increased immunopositive glia in WML compared with NAWM (P < 0.002) ( Figure 4G ). The number of clusterin-positive cells was also significantly increased in WML cores ( Figure 4D )
In contrast to findings in WM, we did not observe any difference between the number of GML and NAGM C1INH, CR1, FH (using polyclonal FH and mAbs Ox-24 and MBI-15) or FHR (MBC-125 antibody) immuno-positive cells ( Figure 5) ; however, clusterin-positive cells were increased in GML cores in comparison to NAGM (P < 0.05, Figure 5D ).
Complement immunolabeling of neurons
We investigated whether neurons and non-neuronal cells (glial; microglia and astrocytes) stained for C components and regulators, and whether the specific C staining differed between NAGM and GML. Positively stained neurons and non-neuronal cells were identified and quantified for each of our panel of antibodies (Tables 4 and 5 ). Overall, total number of neurons did not differ between NAGM and GML cores (data not shown). C1q-positive and C3b-positive non-neuronal cells were increased in GML compared with NAGM (P < 0.0001 and P < 0.0002, respectively) with an accompanying increase in the number of cells positive for regulators and inhibitors (CR1, FH, FHR and clusterin [all P < 0.05, Table 4 ]). However, in contrast, significantly fewer neurons in GML were immuno-stained for C regulators C1INH, CR1, FH (Ox-24) and FHR proteins compared with neurons in NAGM (all P < 0.05); the number of neurons expressing clusterin was similar in GML and NAGM. These data suggest a degree of C dysregulation in GML neurons. In support of this, there was a marked increase in the number of C1q-positive neurons in GML compared with NAGM (P 5 0.0003), but no difference in C3b-positive neurons (Table 5 ).
Testing the relationship between individual C component staining in MS WM and GM
Correlation of C protein staining (on microglia, astrocytes, neurons) was tested for (i) all cores (Table 6 ), (ii) white matter cores only (NAWM, WML; edge and center) ( Table 7 ) and (iii) gray matter cores only (NAGM, GML; edge and center) ( Table 8) . Across all cores, some C components were highly correlated with relevant regulators, while others were not. Total C1q immunopositive cells positively correlated with C3b immuno-stained cells (Pearson's R 2 5 0.70, P < 0.0001) for all TMA cores, demonstrating that C1q binding is closely associated with C3b deposition in progressive MS (Table 6 ). C1q signal also correlated with C1INH (R 2 5 0.48, (Table 6 ). Separate analysis in GM and WM cores showed a positive correlation between all components and regulators in WM (all P < 0.05, Table 7 ); however, in GM many components and regulators showed no correlation, suggesting C dysregulation within cortical GM (Table 8) .
Classification tree analysis identifies C1q1 cell number as a predictor of the lesion state
To investigate whether individual or sets of C components strongly predict WML or GML, classification tree analysis was performed using the rpart library in R (https://cran.r-project.org/web/packages/ rpart/index.html); this tool partitions data to determine tissue classification. Here all cell types were analyzed; neurons and glia. For GM cores, C1q staining stood out as a lesion discriminator; the cutoff for C1q determined by the model was 8.5: if total C1q positive cells was >8.5/core this signified a lesion, and <8.5 signified normal GM. Likewise, the cutoff determined by the model for WM was 13.5. 69% (18/26) of GML tissue cores had >8.5 C1q-positive cells compared with 10% (3/30) of NAGM cores and 88% (54/61) of WML tissue cores had >13.5 C1q-positive cells compared with 2.3% (1/43) of NAWM cores. Although some other C proteins were also predictive, adding in other variables did not improve the capacity of the model to successfully classify cores as either lesion or non-lesion, demonstrating that number of C1q1 cells best discriminates cortical GM and WM MS lesion from normal tissue.
DISCUSSION
TMA methodology is ideally suited for analyzing tissue marker expression, revealing interactions between large numbers of functionally related proteins and identifying proteins or protein sets that correlate with tissue pathology. Our systematic quantitative analysis revealed that increased immunostaining for C proteins is a ubiquitous feature of WM and GM lesions in progressive MS. Furthermore, the findings suggest that C is dysregulated in GM lesions, leaving cortical GM neurons at risk of C-mediated damage because of the presence of C1q, in the absence of key complement regulatory proteins. Indeed, statistical analysis has identified total (neurons and glia) C1q-positive cell number as an independent predictor of lesion presence in GM and WM, suggesting its use as a potential biomarker.
Complement activation immunolabels cells in progressive MS lesions
Anti-C1q and C3b (iC3b/C3b) positively stained microglia/macrophages (HLA-DR1) of WML and neurons and microglia (HLA-DR1) of GML (Tables 1 and 2 and Figure 2 ). The number of antiC3b and -C1q immunolabeled cells were strongly correlated (Pearson coefficient R 2 5 0.70, P < 0.0001), providing further evidence for C activation via the classical pathway on glia and neurons in MS plaques (5, 16, 21) . We have previously demonstrated using double immunolabeling that C1q and iC3b/C3b co-localized on reactive astrocytes, microglia and neurons in MS (16) , and in situ hybridization by ourselves and others showed expression of both C3 and C1qA mRNA in neurons and microglia in MS and other neurodegenerative diseases (23, 28, 32, 37) . C activation is a potential stimulus for microglial activation and expression of reactive oxygen species and pro-inflammatory cytokines, which are associated with neuronal damage and demyelination (1, 6) . Given the paucity of T and B cell lymphocytes in progressive MS lesions (2, 26) , C activation likely represents an important contributor to MS pathology.
Although the above data support local C activation in lesions, immunolabeling cannot readily discriminate whether staining represents protein deposited on the cell surface as a result of activation or within the cell cytoplasm as a consequence of biosynthesis. We performed ISH to show C1QA and C3 mRNA is expressed in cortical neurons co-labeled with the neuron specific marker HuC/D (Figure 3 ). C1QA and C3 mRNA have been consistently demonstrated in MS sections (23, 37) and in glia from Huntington's disease brain tissue (32) . Furthermore antifibrinogen staining of neurons in MS brain was negative supporting the argument that systemic C does not diffuse across the blood-brain barrier in this disease. These data are consistent with the interpretation that the blood-brain barrier is grossly intact in MS (9, 16) , and that neuronal and glial C staining in MS represents local C biosynthesis (28) .
Complement regulation in progressive MS
The increased number of C1q immunolabeled cells in WML is associated with increased C1INH staining on the same cells, supporting on-going activation and regulation of the classical pathway in WML. Several other C regulators were also increased in WML compared with NAWM; FH, the main regulator of the alternative pathway (38) , CR1, a membrane bound activation pathway regulator, and clusterin, a terminal pathway regulator. There was positive correlation between immunolabeling for C3b and its two main regulators, FH and CR1. Staining for FH is complicated by the fact that a battery of homologous FH-related proteins (FHRs) exist to control FH activity; many FH antibodies cross-react with FHRs. To resolve this complexity, we used a panel of anti-FH and anti-FHR antibodies; a polyclonal antibody that detects FH and FHRs, two anti-FH mAbs, one of which (MBI-15) is FH-specific, and a mAb that is specific for FHRs 1, 2 and 5 (MBC-125). Staining with these antibodies demonstrated that both FH and FHRs were present in MS WM lesions, a finding that is in accord with the observed co-localization of FH and FHR on kidney and retinal cells (13) . FHRs are antagonists of FH, blocking its ability to bind C3b and regulate the alternative pathway (10, 11, 13, 15, 31) . The demonstration that both FH and FHRs are present in WM lesions raises the possibility that C regulation by FH is antagonized by FHRs in the lesions. In contrast to the findings in WM, expression of C regulators in GM lesions was minimal, suggesting that C activation is poorly controlled in GM.
Complement activation and dysregulation on neurons contribute to neurodegeneration in cortical gray matter lesions
Neuronal cytoplasm C expression has been described in cultured human cells (33) in animal models (5, 28) and in human post Mann-Whitney U test was used to compare complement proteins and regulator expression on both non-neuronal (glial) cells and on neuronal cells of NAGM and GML. Positive cells were counted per tissue array core (0.28 mm 2 area) and defined as either non-neuronal (Table 4) or neuronal (Table 5) . Median, interquartile range (IQR) and P values are shown. Significance taken at P < 0.05 and shown in BOLD. mortem brain (16, 23, 37) . The ISH images shown here demonstrate C1QA and C3 mRNA expression in neuronal cytoplasm and nuclei, supporting previously published studies (23, 37) . Here we showed that significantly increased numbers of C1q immunolabeled neurons (representing >10% of the total neurons) were present in GML tissue cores. This finding agrees with the increased C1q immunolabeling and C1q mRNA expression described in association with degenerating synapses in MS lesions in hippocampus (22, 37) . There was also increased C3b staining in GM lesions which, together with the reduced numbers of neurons immunolabeling with C regulators in GML compared with GM, provide strong supporting evidence for C dysregulation and activation on neurons in GML. Table 7 . White matter cell counts (NAWM, WML; lesion edge and center).
n/a Table 8 . Gray matter cell counts (NAGM, GML; lesion edge and center). Abbreviations: n/a 5 not applicable, R 2 5 regression coefficient. (Table 6 ), white matter cell counts (Table 7 ) and gray matter cell counts (Table 8 ).
Significant correlation was P < 0.05 and shown in BOLD.
TMA analysis; an appropriate methodology for analysis of a complex innate immune pathway TMA methodology has several advantages over traditional IHC methods; it requires only small amounts of formalin fixed tissue and much reduced quantities of reagents, including expensive antibodies, compared with traditional IHC (31) . Furthermore, the TMA approach samples a consistent area of lesion, reduces variability of experimental conditions and increases reliability of immunostaining data, making it an ideal technique to validate newly generated antibodies (36) ; and compare sets of antibodies as used in this study (10, 11, 31) . One possible criticism of this approach when applied to MS tissue is the debate regarding heterogeneity of MS plaque immunopathology (3, 21) such that individual cores will show variations in pathology. To ensure tissue pathology is uniform between TMA cores we only selected chronic active plaques and ensured that the severity of inflammation and pathology was uniform within lesion type by controlling for severity of myelin loss, microglial number and activation status (anti-Iba and anti-HLA-DR) and T and B cell immunostaining.
CONCLUSION
The C pathways are pivotal for the CNS innate immune response (24) ; previous studies have shown an association between individual C proteins and MS pathology (5, 16, 21, 37) ; here, using TMA methodology in MS tissue in conjunction with control tissues and statistical analyses, we have demonstrated a role for C in progressive MS in both WM and GM lesions and demonstrated an association between functionally related C proteins and tissue pathology. Statistical modeling revealed that the number of C1q-positive cells in WM or GM was highly predictive of a lesion. In GM lesions, the data suggest that C activation is associated with dysregulation; a finding present in other neuroinflammatory diseases such as retinal inflammation in Age Related Macular Degeneration (AMD) (20, 34) . AMD is associated with a Tyr402His amino acid substitution in FH and dysregulation and uncontrolled activation of C in the retina. The retinal pathology typically includes deposits of C3, C3d, iC3b, terminal pathway components, clusterin and FHRs (38) . In our study, evidence for C dysregulation in GML is provided by an increase of C1q-positive neurons with reduced immuno-labeling for the regulators FH, FHR 1/2/5 and C1INH compared with NAGM. With regard to clinical relevance, measurement of C proteins in serum and CSF is now validated as a biomarker of tissue inflammation in MS (15) . Here we show that tissue-associated C proteins also mark disease in progressive MS and may guide future therapeutic approaches targeting the classical pathway.
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